BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 23916803)

  • 1. Prognosis of unexpected and expected pathologic N1 non-small cell lung cancer.
    Shin S; Kim HK; Choi YS; Kim K; Kim J; Shim YM
    Ann Thorac Surg; 2013 Sep; 96(3):969-75; discussion 975-6. PubMed ID: 23916803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Predictors of Nodal Metastases in Peripherally Clinical T1a N0 Non-Small Cell Lung Cancer.
    Ghaly G; Rahouma M; Kamel MK; Nasar A; Harrison S; Nguyen AB; Port J; Stiles BM; Altorki NK; Lee PC
    Ann Thorac Surg; 2017 Oct; 104(4):1153-1158. PubMed ID: 28551047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mediastinoscopy might not be necessary in patients with non-small cell lung cancer with mediastinal lymph nodes having a maximum standardized uptake value of less than 5.3.
    Lee BE; Redwine J; Foster C; Abella E; Lown T; Lau D; Follette D
    J Thorac Cardiovasc Surg; 2008 Mar; 135(3):615-9. PubMed ID: 18329480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upstaging and survival after robotic-assisted thoracoscopic lobectomy for non-small cell lung cancer.
    Toosi K; Velez-Cubian FO; Glover J; Ng EP; Moodie CC; Garrett JR; Fontaine JP; Toloza EM
    Surgery; 2016 Nov; 160(5):1211-1218. PubMed ID: 27665362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fusion positron emission/computed tomography underestimates the presence of hilar nodal metastases in patients with resected non-small cell lung cancer.
    Carrillo SA; Daniel VC; Hall N; Hitchcock CL; Ross P; Kassis ES
    Ann Thorac Surg; 2012 May; 93(5):1621-4. PubMed ID: 22429676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologic lymph node staging practice and stage-predicted survival after resection of lung cancer.
    Osarogiagbon RU; Allen JW; Farooq A; Berry A; O'Brien T
    Ann Thorac Surg; 2011 May; 91(5):1486-92. PubMed ID: 21524460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic analysis of patients with unsuspected pathologic N1 non-small cell lung cancer].
    Xie M; Mei X; Li T; Sun X; Xu S; Ma D
    Zhonghua Zhong Liu Za Zhi; 2015 May; 37(5):387-91. PubMed ID: 26463033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contrast enhanced CT versus integrated PET-CT in pre-operative nodal staging of non-small cell lung cancer.
    Ceylan N; Doğan S; Kocaçelebi K; Savaş R; Çakan A; Çağrici U
    Diagn Interv Radiol; 2012; 18(5):435-40. PubMed ID: 22374706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of multiple metastatic nodal stations on survival in patients with resectable N1 and N2 nonsmall-cell lung cancer.
    Kang CH; Ra YJ; Kim YT; Jheon SH; Sung SW; Kim JH
    Ann Thorac Surg; 2008 Oct; 86(4):1092-7. PubMed ID: 18805138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are discordant positron emission tomography and pathological assessments of the mediastinum in non-small cell lung cancer significant?
    Tandberg DJ; Gee NG; Chino JP; D'Amico TA; Ready NE; Coleman RE; Kelsey CR
    J Thorac Cardiovasc Surg; 2013 Oct; 146(4):796-801. PubMed ID: 23870158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of bulky swollen lymph nodes in cN1 non-small cell lung cancer patients.
    Samejima J; Nakao M; Matsuura Y; Uehara H; Mun M; Nakagawa K; Motoi N; Masuda M; Ishikawa Y; Okumura S
    Jpn J Clin Oncol; 2015 Nov; 45(11):1050-4. PubMed ID: 26355162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high.
    Turkmen C; Sonmezoglu K; Toker A; Yilmazbayhan D; Dilege S; Halac M; Erelel M; Ece T; Mudun A
    Clin Nucl Med; 2007 Aug; 32(8):607-12. PubMed ID: 17667432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment.
    Galimberti V; Ribeiro Fontana SK; Maisonneuve P; Steccanella F; Vento AR; Intra M; Naninato P; Caldarella P; Iorfida M; Colleoni M; Viale G; Grana CM; Rotmensz N; Luini A
    Eur J Surg Oncol; 2016 Mar; 42(3):361-8. PubMed ID: 26746091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. False-positivity of mediastinal lymph nodes has negative effect on survival in potentially resectable non-small cell lung cancer.
    Iskender I; Kadioglu SZ; Cosgun T; Kapicibasi HO; Sagiroglu G; Kosar A; Kir A
    Eur J Cardiothorac Surg; 2012 Apr; 41(4):874-9. PubMed ID: 22423060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer.
    Lin Y; Lin WY; Kao CH; Yen KY; Chen SW; Yeh JJ
    Anticancer Res; 2012 Nov; 32(11):5087-91. PubMed ID: 23155285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Misstagings and Risk Factors of Occult Nodal Disease in Non-Small Cell Lung Cancer.
    Dyas AR; King RW; Ghanim AF; Cerfolio RJ
    Ann Thorac Surg; 2018 Nov; 106(5):1492-1498. PubMed ID: 29908981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of pathologic node-negative clinical stage IA lung adenocarcinoma for optimal candidates undergoing sublobar resection.
    Tsutani Y; Miyata Y; Nakayama H; Okumura S; Adachi S; Yoshimura M; Okada M
    J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1365-71. PubMed ID: 22883546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of primary surgery with T4 non-small cell lung cancer during a 25-year period in a single center: the benefit is worth the risk.
    Yildizeli B; Dartevelle PG; Fadel E; Mussot S; Chapelier A
    Ann Thorac Surg; 2008 Oct; 86(4):1065-75; discussion 1074-5. PubMed ID: 18805134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of clinical n1 non-small cell lung cancer.
    Kim D; Choi YS; Kim HK; Kim K; Kim J; Shim YM
    Thorac Cardiovasc Surg; 2014 Mar; 62(2):103-8. PubMed ID: 23319312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete thoracic mediastinal lymphadenectomy leads to a higher rate of pathologically proven N2 disease in patients with non-small cell lung cancer.
    Cerfolio RJ; Bryant AS; Minnich DJ
    Ann Thorac Surg; 2012 Sep; 94(3):902-6. PubMed ID: 22776083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.